Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025Seeking Alpha • 12/18/25
Recursion Pharmaceuticals, Inc. (RXRX) Discusses Updated Safety and Efficacy Data from TUPELO Phase I/II Study of REC-4881 in FAP TranscriptSeeking Alpha • 12/08/25
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 WeeksGlobeNewsWire • 12/08/25
Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/05/25
Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025GlobeNewsWire • 12/01/25
Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock?The Motley Fool • 11/24/25
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Jefferies London Healthcare Conference 2025 TranscriptSeeking Alpha • 11/22/25
Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?Seeking Alpha • 11/18/25
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/05/25
Recursion Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 11/05/25
Earnings Preview: Recursion Pharmaceuticals (RXRX) Q3 Earnings Expected to DeclineZacks Investment Research • 10/29/25
Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5thGlobeNewsWire • 10/28/25